{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:20:07Z","timestamp":1783178407967,"version":"3.54.6"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40290-026-00615-z","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:30:19Z","timestamp":1782131419000},"page":"287-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Framework for Standardising Toxicity Management Guidelines in Oncology Clinical Trials"],"prefix":"10.1007","volume":"40","author":[{"given":"Sanjana","family":"Singarayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Lloyd-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9727-7668","authenticated-orcid":false,"given":"Ken","family":"Twomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"615_CR1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH E6(R3) Guideline for Good Clinical Practice: Annex 2 \u2013 Step 2 draft. Geneva: ICH; 2024. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Annex%202_Step2_DraftGuideline_2024_1024_0.pdf. Accessed 10 Apr 2025."},{"key":"615_CR2","unstructured":"European Medicines Agency. Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA\/CHMP\/SWP\/28367\/07 Rev. 1). European Medicines Agency. 2017.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational_en.pdf. Accessed 10 Apr 2025."},{"key":"615_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Chen S, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Sig Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"615_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"615_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51(4):260\u201377. https:\/\/doi.org\/10.1016\/j.resinv.2013.09.001.","journal-title":"Respir Investig"},{"key":"615_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","volume":"6","author":"M Schwaiblmair","year":"2012","unstructured":"Schwaiblmair M, Behr W, Haeckel T, M\u00e4rkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63\u201374. https:\/\/doi.org\/10.2174\/1874306401206010063.","journal-title":"Open Respir Med J"},{"issue":"10354","key":"615_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","volume":"400","author":"M Wijsenbeek","year":"2022","unstructured":"Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(22)01052-2.","journal-title":"Lancet"},{"key":"615_CR8","unstructured":"Bridwell G. Specific emerging toxicities of concern: Mechanisms and management of ADC-related lung toxicity. Lecture, presented at: MASCC Annual Meeting; 2025 Jun 27; Seattle, USA."},{"issue":"8","key":"615_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? Oncologist. 2022;27(8):625\u201336. https:\/\/doi.org\/10.1093\/oncolo\/oyac074.","journal-title":"Oncologist"},{"key":"615_CR10","unstructured":"National Comprehensive Cancer Network\u00ae (NCCN\u00ae). NCCN Clinical Practice Guidelines in Oncology. Version 1.2025. National Comprehensive Cancer Network\u00ae; 2024.\u00a0https:\/\/www.nccn.org\/guidelines\/category_1. Accessed 10 Apr 2025."},{"key":"615_CR11","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/apt.18271","volume":"60","author":"A Fettiplace","year":"2024","unstructured":"Fettiplace A, Marcinak J, Merz M, Zhang H-T, Kikuchi L, Regev A, et al. Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients. Aliment Pharmacol Ther. 2024;60:1293\u2013307. https:\/\/doi.org\/10.1111\/apt.18271.","journal-title":"Aliment Pharmacol Ther"},{"key":"615_CR12","first-page":"73","volume":"6","author":"S David","year":"2010","unstructured":"David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 2010;6:73\u201380.","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"615_CR13","unstructured":"US Food and Drug Administration. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. https:\/\/www.fda.gov\/media\/116737\/download Accessed 9 Apr 2026."},{"key":"615_CR14","volume-title":"Drug-induced liver injury: premarketing clinical evaluation. guidance for industry","author":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER)","year":"2009","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Drug-induced liver injury: premarketing clinical evaluation. guidance for industry. FDA; 2009."},{"key":"615_CR15","unstructured":"National Institute of Allergy and Infectious Diseases. DAIDS adverse event grading tables. National Institute of Allergy and Infectious Diseases. 2017.\u00a0https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables. Accessed 10 Apr 2025."},{"issue":"4","key":"615_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"615_CR17","doi-asserted-by":"publisher","first-page":"R741","DOI":"10.1016\/j.cub.2012.07.024","volume":"22","author":"T Niccoli","year":"2012","unstructured":"Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol. 2012;22(17):R741-752. https:\/\/doi.org\/10.1016\/j.cub.2012.07.024.","journal-title":"Curr Biol"},{"issue":"13","key":"615_CR18","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","volume":"40","author":"JM Unger","year":"2022","unstructured":"Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474\u201386. https:\/\/doi.org\/10.1200\/JCO.21.02377.","journal-title":"J Clin Oncol"},{"issue":"3","key":"615_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030298","volume":"15","author":"AC Brabete","year":"2022","unstructured":"Brabete AC, Greaves L, Maximos M, Huber E, Li A, L\u00ea ML. A sex- and gender-based analysis of adverse drug reactions: A scoping review of pharmacovigilance databases. Pharmaceuticals (Basel). 2022;15(3):298. https:\/\/doi.org\/10.3390\/ph15030298.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"615_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32. https:\/\/doi.org\/10.1186\/s13293-020-00308-5.","journal-title":"Biol Sex Differ"},{"key":"615_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00520-023-08219-y","volume":"32","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. MASCC\/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update. Support Care Cancer. 2024;32:57. https:\/\/doi.org\/10.1007\/s00520-023-08219-y.","journal-title":"Support Care Cancer"},{"issue":"1","key":"615_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01886-7","volume":"8","author":"D Teodoro","year":"2025","unstructured":"Teodoro D, Naderi N, Yazdani A, Zhang B, Bornet A. A scoping review of artificial intelligence applications in clinical trial risk assessment. NPJ Digit Med. 2025;8(1):486. https:\/\/doi.org\/10.1038\/s41746-025-01886-7.","journal-title":"NPJ Digit Med"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00615-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:04:48Z","timestamp":1783177488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00615-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00615-z","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"19 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are current or former employees of AstraZeneca and hold stock and stock options. Sanjana Singarayer, Heidi Lloyd-Williams, Abigail Morrison, and Ken Twomey declare that they have no other conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Organisational approval for publication was obtained in accordance with AstraZeneca publication policies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analysed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the development of the framework, reviewed and approved the final manuscript, and agree to be accountable for its content.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}